Abstract：Objective：To observe the clinical effect of moxibustion combined with Entecavir for chronic hepatitis B (CHB) of spleen-kidney yang deficiency type. Methods：A total of 90 cases of CHB patients of spleen-kidney yang deficiency type were selected and divided into the control group and the treatment group according to the random number table method， with 45 cases in each group. Four cases in the treatment group were dropped out due to voluntary withdrawal from the study，and finally，41 cases were included in the treatment group. The control group was treated with Entecavir Dispersible Tablets，and the treatment group was additionally treated with moxibustion based on the treatment of the control group. Both groups were treated for 3 months，followed up for 6 months. Clinical effects，traditional Chinese medicine(TCM) syndrome scores， liver function indexes [alanine aminotransferase (ALT)， aspartate aminotransferase (AST)，and total bilirubin (TBil)]，T lymphocyte subsets indexes (CD3 + ，CD4 + ，and CD4 + / CD8+values)，and the incidence of adverse reactions were compared between the two groups. Results： After treatment，the total clinical effective rate was 97.56% in the treatment group，higher than that of 82.22% in the control group (P＜0.05). The scores of intolerance to cold and cold limbs，soreness and weakness of waist and knees，poor appetite，and fatigue and lack of strength in the two groups were decreased when compared with those before treatment (P＜0.05)， and the above four TCM syndrome scores in the treatment group were lower than those in the control group (P＜0.05). The levels of ALT， AST，and TBil in the two groups were decreased when compared with those before treatment (P＜0.05)， and the levels of ALT，AST，and TBil in the treatment group were lower than those in the control group (P＜ 0.05). The levels of CD3 + ，CD4 + ，and CD4 + /CD8 + values in the two groups were increased when compared with those before treatment (P＜0.05)， and the levels of CD3+， CD4+， and CD4+ /CD8 +value in the treatment group were higher than those in the control group (P＜0.05). The incidence of adverse reactions was 8.89% in the control group and 9.76% in the treatment group，no significant difference was found in the comparison between the two groups (P＞0.05). Conclusion：In the treatment of CHB of spleen-kidney yang deficiency type，the additional use of moxibustion based on Entecavir Dispersible Tablets can enhance clinical effects， effectively improve clinical symptoms and liver function and regulate immune function， with good safety.